Clinical trials: Heart Transplantation
Invasive Fungal Infections
Retrospective Study of Invasive Fungal Infections With Filamentous Fungi in Heart Transplant Patients
Invasive filamentous fungal infections (aspergillosis, scedosporiosis, mucormycosis, fusarium wilt) are common and serious in immunocompromised subjects and particularly organ transplant patients.
- Trial name
- IMI-CART (NCT06498310)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Stem Cell Transplantation, Ventricular Dysfunction, Left
The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)
The technique of transplanting progenitor cells into a region of damaged myocardium, termed cellular cardiomyoplasty, is a potentially new therapeutic modality designed to replace or repair necrotic, scarred, or dysfunctional…
- Trial name
- TAC-HFT (NCT00768066)
- Testing
- Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Miami
Graft Rejection
Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection
This trial was to examine the impact of everolimus and reduced dose of cyclosporine on efficacy and safety compared to mycophenolate mofetil and a standard dose of cyclosporine in heart transplant recipients.
- Trial name
- NCT00300274
- Testing
- everolimus, mycophenolate mofetil, cyclosporine
- Where
- 64 sites in United States, Argentina and 13 more
- Volunteers
- 721 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Jarvik 2000 Heart as a Bridge to Cardiac Transplantation - Pivotal Trial
The purpose of the study is to determine the safety and effectiveness of the Jarvik 2000 Heart as a bridge to heart transplantation in end-stage heart failure patients who are approved heart transplant candidates.
- Trial name
- NCT00591799
- Testing
- The Jarvik 2000 Ventricular Assist System
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Jarvik Heart, Inc.
Heart Transplant
US National OCS Heart Perfusion (OHP) Registry
This Registry is a sponsor initiated, multi-center, observational post-approval registry with independent academic oversight.
- Trial name
- NCT05915299
- Testing
- OCS Heart
- Where
- 37 sites in United States
- Volunteers
- 100,000 people
- Sponsor
- TransMedics
Heart Failure
Prognosis of Heart Transplanted Patients With Heart Failure
Heart transplantation is the most effective treatment for end-stage heart failure, advanced cardiomyopathy, and complex congenital heart disease with severe heart failure or hypoxia.
- Trial name
- RE-START (NCT05775432)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Cardiorenal Syndrome, Chronic Allograft Nephropathy
Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
We hypothesize that paricalcitol and calcitriol in dose-dependent manner are effective for the management of chronic allograft dysfunction (CAD), protection and repair of kidney and heart, management of chronic renocardiac…
- Trial name
- NCT01265615
- Testing
- Paricalcitol, Calcitriol, Cholecalciferol
- Where
- 2 sites in Netherlands, Russia
- Volunteers
- 109 people
- Sponsor
- Ural State Medical University
Organ Transplant
Trial to Compare the SherpaPak™ Device vs Cold Storage
The Investigator's are doing this study to see which method of organ preservation leads to better outcomes for donated hearts. There are two methods of organ preservation. The first method is the use of cold storage.
- Trial name
- SherpaPak (NCT05194514)
- Testing
- SherpaPak™ Device, Cold Storage
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Myocardial Infarction, Percutaneous Coronary Intervention
Text Message Intervention to Improve Cardiac Rehab Participation
Cardiac rehabilitation (CR) is strongly recommended for patients with coronary heart disease. However, patient enrollment and completion of cardiac rehabilitation is low.
- Conditions
- Myocardial Infarction, Percutaneous Coronary Intervention, Coronary Artery Bypass Surgery, Heart Valve Repair or Replacement
- Trial name
- NCT03346278
- Testing
- Text Messaging Intervention
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Washington
Myocardial Infarction, Stem Cell Transplantation
Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction
The benefit of current stem cell transplantation therapy for myocardial infarction is limited by low survival rate for stem cell.
- Conditions
- Myocardial Infarction, Stem Cell Transplantation, Angioplasty, Transluminal, Percutaneous Coronary
- Trial name
- STEM-AMI (NCT00979758)
- Testing
- Atorvastatin and mononuclear cells transplantation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
H1N1 Influenza
Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation
Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines. In these patients the investigators will measure the specific antibody production.
- Trial name
- NCT01008683
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Hadassah Medical Organization
Heart Transplantation
Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients
In this study two immunosuppressive regimens (everolimus in combination with cyclosporine microemulsion and mycophenolate mofetil with cyclosporine microemulsion) with reduced dose cyclosporine microemulsion are compared in…
- Trial name
- NCT00170859
- Testing
- Everolimus
- Where
- Germany
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant Recipient, Kidney Transplant; Complications
Vascular Complications After Kidney Transplantation
To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients…
- Conditions
- Kidney Transplant Recipient, Kidney Transplant; Complications, Transplant Renal Artery Stenosis, Renovascular Disease
- Trial name
- DAN-PTRAIII (NCT07531966)
- Testing
- Catheter-based angiography, Measurement of translesional pressure gradients, Intravascular ultrasound (IVUS)
- Where
- 3 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Complete DiGeorge Anomaly, DiGeorge Syndrome
Thymus Transplantation Safety-Efficacy
Complete DiGeorge anomaly (cDGA) is a disorder in which there is no thymus function. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection.
- Conditions
- Complete DiGeorge Anomaly, DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Syndrome
- Trial name
- NCT01220531
- Testing
- Cultured Thymus Tissue
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Cytomegalovirus Infections, Heart Transplantation
A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age
This open label study will assess the pharmacokinetics and the safety and tolerability of Valcyte (valganciclovir) powder for oral solution in neonatal and infant heart transplant patients < 4 months of age.
- Trial name
- NCT01165580
- Testing
- valganciclovir [Valcyte]
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 17 people
- Sponsor
- Hoffmann-La Roche
Heart Transplantation
Evidence Based Evaluation and Acceptance of Donor Hearts for Transplantation
The proposed research will provide evidence-based strategies for the evaluation and acceptance of donor hearts for transplantation.
- Trial name
- DHS (NCT02376387)
- Where
- 10 sites in United States
- Volunteers
- 4,333 people
- Sponsor
- Stanford University
Kidney Transplantation, Cardiovascular Diseases
Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients
The purpose of this research study is to determine if adding or increasing the dose of CellCept while lowering the dose of tacrolimus (Prograf or Advagraf) or cyclosporine (Neoral), and/or steroids can reduce the likelihood of…
- Trial name
- MMCR (NCT01213394)
- Testing
- mycophenolate mofetil, standard immunosuppression
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Ramesh Prasad
Heart Transplant, Small Intestine Transplant
Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children
Solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. However, the same immunosuppressive medications that are required to prevent the child's immune system from…
- Conditions
- Heart Transplant, Small Intestine Transplant, Kidney Transplant, Liver Transplant
- Trial name
- NCT02182986
- Testing
- transplant, Immunosuppressive Drugs
- Where
- 7 sites in United States
- Volunteers
- 944 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Heart Transplant Rejection
Cardiac Transplant Metabolomics With and Without Rejection
Patient who received a heart transplant may develop organ rejection. Currently, an invasive biopsy of the heart needs to be performed to diagnose rejection.
- Trial name
- ANTIPARTICLE (NCT05772442)
- Testing
- Extra blood samples (5-10 mL) drawn
- Volunteers
- 100 people
- Sponsor
- Western University, Canada
Cardiac Allograft Vasculopathy, Heart Transplant Recipients
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
All people who have a heart transplant are at risk for developing cardiac allograft vasculopathy (CAV). CAV means narrowing of the heart transplant vessels, which is associated with poor heart transplant function.
- Trial name
- NCT01278745
- Testing
- Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
- Where
- 24 sites in United States
- Volunteers
- 362 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)